Merck & Co.

Merck’s moat rests on a familiar but still powerful pharmaceutical stack: patented molecules and biologics, regulatory approvals across many indications, global trial execution, payer and provider relationships, and the manufacturing discipline required for high-volume sterile biologics and vaccines. KEYTRUDA’s scale alone gives Merck unusually strong bargaining power, data advantages, and room to fund follow-on trials that smaller challengers cannot easily match.

The weakness in that moat is concentration. Merck’s own disclosures show that KEYTRUDA remains enormous relative to the rest of the portfolio, while GARDASIL remains a major vaccine franchise despite a sharp 2025 decline. That leaves Merck exposed to patent expiry, biosimilar pressure, procurement shifts, and technology-transfer efforts that reduce the premium attached to a single incumbent manufacturer.

Merck is not naturally exposed to the easiest forms of software-style decentralization. Its leading products sit inside tightly regulated, capital-intensive supply chains where validation, comparability, sterility, pharmacovigilance, and cold-chain discipline matter more than open distribution alone.

Pressure is still possible, but it comes through slower structural channels: biosimilar pathways, voluntary licensing and patent-pool models, regional technology transfer, modular or continuous biomanufacturing, and public-sector procurement that seeds multiple qualified suppliers instead of one dominant franchise. Those mechanisms are real, but for Merck they are medium- to long-horizon forces rather than immediate consumer-led disruption.